ClinicalTrials.gg
RecruitingNCT05408247NAC-AUDUpdated Mar 16, 2023

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

A Phase 4 interventional study of N-acetyl cysteine and Placebo in Alcohol Use Disorder (AUD), sponsored by University of Sydney. Recruiting at 3 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by University of Sydney · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing acetylcysteine in Alcoholism — 2 open to participants now, 2 under way, none of them phase 3. Acetylcysteine · Alcoholism.

Planned enrollment
Largest of 12
280 · median 80
Started
2023
with 1 other
Phase 4
2 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
University of Sydney

Among the 12 studies testing acetylcysteine in Alcoholism, this one has the largest planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 4, and was the 11th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

2 of the 12 studies testing acetylcysteine in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About acetylcysteine

Acetylcysteine: first FDA approval 1963 (MUCOMYST). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing acetylcysteine in Alcoholism, or all of them as a file.
02

Study summary

To explore the effectiveness of n-acetylcysteine in improving treatment outcomes for alcohol use disorder in a double-blind randomised placebo-controlled trial.

Read the detailed description

Australia urgently requires new treatment strategies for the treatment of alcohol dependence. Although alcohol use disorders are a leading cause of preventable death in Australia, their treatment is generally not evidence based. The medications currently approved for use in Australia for the management of alcohol dependence have limited efficacy, and existing research does not address the heterogeneity of treatment response. Targeted personalised medicine addresses this heterogeneity with better medicine selection for patients based on their genotype and clinical comorbidities.

Following on from a recent pilot study conducted by CI Morley (NCT03879759), this project will evaluate the clinical efficacy and tolerability of NAC, relative to a placebo, in heavy drinkers. We hypothesise that NAC-treated participants will be better able to achieve a reduction in heavy drinking. We will utilise a double-blind, randomised, controlled design. A sample of 280 individuals will receive 12 weeks of treatment with NAC (2400 mg/day) or placebo.

03

Conditions studied

  • Alcohol Use Disorder (AUD)

Browse trials for

Keywords

  • N-acetyl Cysteine
  • NAC
  • Alcohol Dependence
  • N-acetylcysteine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Alcohol Use Disorder according to the criteria
  • A desire to reduce or stop drinking
  • Consumed at least 21 standard drinks per week or 2 heavy drinking days per week (HDD: ≥ 5 standard drinks/day for men; ≥4 for women) in the month prior to screening
  • Adequate cognition and English language skills to give valid consent and complete research interviews
  • Stable housing
  • Willingness to give written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation (women will be advised to use reliable during the trial and a pregnancy test will be performed were necessary)
  • Concurrent use of any psychotropic medication other than antidepressants (provided these are taken at stable doses for at least two months)
  • Any substance dependence other than nicotine
  • Clinically unstable systemic medical (e.g. cancer, end stage liver disease: e.g. MELD score ≥ 10) or psychiatric disorder (e.g. active psychosis, borderline personality disorder, active suicide risk: e.g. MADRAS item 10 score of 6) that precludes trial participation
  • Concurrent use of selenium, vitamin D or other anti-oxidants
  • Any alcohol pharmacotherapy within the past month
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    N-acetyl Cysteine

    Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks + Standard of Care: Medical Management.

    Drug: N-acetyl cysteine

  • Placebo comparator
    Placebo

    Matched placebo Generic name: dicalcium phosphate Strength: 600mg per capsule Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks. + Standard of Care: Medical Management.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Heavy Drinking Days

    Reduction in Heavy Drinking Days (HDD; defined as 4 or more drinks in a day for women and five or more drinks in a day for men). This will be measured by the Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 24 weeks

Secondary outcomes

  1. Changes in Liver Function

    Liver Function will be assessed through blood sample at baseline. We will measurement levels of enzyme gamma-glutamyl transferase (GGT), aspartate transaminase (AST), and alanine transaminase (ALT).

    Time frame: 24 weeks

  2. Absence of any HDD

    Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 24 weeks

Other outcomes

  1. Cost-Efficacy

    Examine the cost-efficacy between NAC and placebo from both health sector and societal perspectives. Measured by Disability-Adjusted Life Years (DALYs)

    Time frame: 12 weeks

  2. Changes in Alcohol Craving

    As measured by the Alcohol Craving Experience Questionnaire (ACEQ). Higher scores indicate more severe craving.

    Time frame: 24 weeks

  3. Mean alcohol consumption per drinking day

    Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 24 weeks

  4. Change in dependence Severity

    Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.

    Time frame: 24 weeks

  5. Changes in Anxiety

    Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.

    Time frame: 24 weeks

  6. Changes in Depression

    Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.

    Time frame: 24 weeks

  7. Changes in Stress

    Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.

    Time frame: 24 weeks

  8. Sleep Disturbances

    As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia.

    Time frame: 24 weeks

  9. Lifetime Consequences related to Drinking

    To examine the adverse consequences a participant has experienced in their lifetime due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Lifetime Edition (DrInC-2L). Higher scores indicate more consequences.

    Time frame: Baseline

  10. Recent Consequences related to Drinking

    To examine the adverse consequences a participant has experienced in the last 3 months due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Recent Edition (DrInC-2R). Higher scores indicate more consequences.

    Time frame: 12 weeks

  11. Changes in Consequences related to Drinking

    To examine the change in adverse consequences a participant has experienced across the trial due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured by comparing the Drinker Inventory of Consequences Recent Edition (DrInC-2R) and the Drinker Inventory of Consequences Lifetime Edition (DrInC-2L). Higher scores indicate more consequences.

    Time frame: 24 weeks

  12. Drinking Dairy

    Daily texts will be sent out to participants querying the amount of alcohol they have consumed. Participant responses to this will be recorded. This will be managed through SEMA software.

    Time frame: 12 weeks

  13. Nicotine Dependence

    Measured by the Fagerstrom Test for Nicotine Dependence (FTND). This test has a minimum score of 0 and a maximum score of 10. Higher scores indicate a more intense physical dependence on nicotine.

    Time frame: Baseline

  14. Changes in Suicidal Ideation

    As measured by the Suicidal Ideation Attributes Scale (SIDAS). This scale has a minimum score of 0 and a maximum score of 50. Higher scores indicate more severe suicidal thoughts.

    Time frame: 24 weeks

  15. Changes in Information Gathering ability

    As measured by the Caravan Spotter task of the Cognitive Impulsivity Suite (CIS). This measures information gathering through a perceptual decision making task whereby the target is initially ambiguous but progressively becomes clearer.

    Time frame: 24 weeks

  16. Changes in Attentional Control

    As measured by the Bounty Hunter task of the Cognitive Impulsivity Suite (CIS). This measures attentional control using a Go/No Go task.

    Time frame: 24 weeks

  17. Changes in Monitoring of Feedback

    As measured by the Prospectors Gamble task of the Cognitive Impulsivity Suite (CIS). This involves a probabilistic reverse learning task to measure monitoring of feedback.

    Time frame: 24 weeks

  18. Irritability

    As measured by the Brief Irritability Test (BITe). This test has a minimum score of 0 and a maximum score of 30. Higher scores indicate greater irritability.

    Time frame: Baseline

  19. Changes in Physical Activity

    To assess an individuals' health based on the previous 7 days of physical activity. This is measured by the International Physical Activity Questionnaire (IPAQ-Long). We are interested in whether across treatment, answers to this questionnaire will change.

    Time frame: 24 weeks

  20. Changes in Quality of Life

    To assess whether treatment can change quality of life as measured by the short form Health Survey (SF-36). This survey has 36 items that measure 8 domains of health, including: physical functioning, physical role limitations, bodily pain, general health perceptions, energy/vitality, social functioning, emotional role limitations and mental health. The scores are transformed to range from 0 (worst possible health) to 100 (best possible health).

    Time frame: 24 weeks

  21. Changes in Quality of Life

    As measured by the EQ-5D-5L. This instrument measures 5 different domains of life including: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is assessed by one question. This instrument has a minimum score of 0 (worst possible health) and a maximum score of 1 (best possible health).

    Time frame: 24 weeks

  22. Changes in ability to inhibit prepotent responses

    As measured by the Stroop Colour Word Test. This test measures ability to inhibit prepotent responses and processing speed. This is assessed through the time it takes for an individual to appropriately select an incongruent response. For example, selecting "black" for the word "black" that is coloured in "green". Higher scores indicate worse performance.

    Time frame: 24 weeks

  23. Changes in processing speed

    As measured by the Trail Making Task (TMT). This test measures the ability to an individual to process visual stimuli, as measured in time. In the TMT Part A, individuals are instructed to draw a line between numbers, 1-2-3-4-5. Higher time indicates slower processing speed. In the TMT Part B individuals are instructed to switch between drawing lines between numbers and letters, for example 1-A-2-B-3-C. Higher time indicates worse processing speed and switching ability.

    Time frame: 24 weeks

  24. Changes in DSM-5 PTSD symptomology

    As measured by the PCL-5. This self-report questionnaire lists 20-items that assess DSM-5 PTSD criteria. A higher score indicates greater severity

    Time frame: 24 weeks

  25. Changes in use of Health Services

    As measured by the Brief Health Services Use Questionnaire. This questionnaire assesses Health Service Use across the last 3 months.

    Time frame: 24 weeks

  26. Hangover Diary

    Daily texts will be sent out to participants querying the hangover symptoms they are experiencing, if any. Participant responses to this will be recorded. This will be managed through SEMA software.

    Time frame: 12 weeks

  27. Using Redox Markers to predict treatment response

    We will use blood samples collected at baseline to measure redox markers (GPxBC, GSHBC). At the end of treatment we will see whether these markers are predictive of treatment response

    Time frame: Baseline

  28. Changes in Redox Markers

    We will use blood samples collected at baseline and wk 12 to measure changes in redox markers (GPxBC, GSHBC)

    Time frame: 12 weeks

07

Study locations

1 of 3 sites recruiting
  • Drug Health Services, Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
    Recruiting
  • Cornwall Street Medical Centre (UQ Health Care)
    Annerley, Queensland 4103, Australia
    Not yet recruiting
  • Turning Point
    Richmond, Victoria 3121, Australia
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Nov 2025, 33 months after the start.

Of 24 phase 4 interventional studies under Alcoholism, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 83. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 7, 2022
StartActual
Feb 16, 2023
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2026
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05408247
Lead sponsor
University of Sydney
Collaborators
Monash University
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Feb 16, 2023
Primary completion
Nov 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 16, 2023

Study contacts

Kirsten Morley, PhD
Contact
Kirsten.morley@sydney.edu.au
61295153636
Paul Haber, MBBS
Contact
paul.haber@sydney.edu.au

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion